The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Through 2030?
The ribonucleic acid (rna) therapy clinical trials market has demonstrated steady expansion over recent years. Its valuation is anticipated to climb from $2.7 billion in 2025 to $2.83 billion in 2026, advancing at a compound annual growth rate (CAGR) of 4.8%. The increase observed during earlier periods stemmed from a combination of factors, including a limited array of rna-based therapeutic solutions, the substantial expenses associated with early-stage clinical trials, difficulties in securing regulatory approvals, inadequate public understanding of rna therapies, and a prevailing reliance on conventional therapeutic methods.
The market size for ribonucleic acid (RNA) therapy clinical trials is anticipated to demonstrate steady expansion in the upcoming years. It is projected to reach $3.4 billion in 2030, growing at a compound annual growth rate (CAGR) of 4.7%. The expected growth during the forecast period can be attributed to advancements in RNA delivery technologies, increased funding for rare disease and anticancer research, growing collaboration between biotechnology and pharmaceutical companies, the rising adoption of personalized medicine approaches, and the expansion of global clinical trial networks. Prominent trends expected in the forecast period include a rising number of RNA therapy clinical trials across various therapeutic areas, an increasing focus on rare disease and anticancer RNA therapeutics, the expansion of mRNA vaccine and self-amplifying RNA therapy trials, the adoption of CRISPR and RNA editing-based therapy trials, and the integration of advanced delivery platforms and oligonucleotide conjugates.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
What Major Growth Factors Are Impacting The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The anticipated expansion of the ribonucleic acid (RNA) therapy clinical trials market is linked to the rising prevalence of infectious diseases. These diseases are ailments resulting from harmful microorganisms like bacteria, viruses, fungi, or parasites that penetrate the body, reproduce, and compromise well-being. A primary factor contributing to the increase in infectious diseases is the surge in international travel, enabling pathogens to disseminate quickly across diverse areas and communities. Clinical trials for ribonucleic acid (RNA) therapy contribute to fighting infectious diseases by facilitating the creation and assessment of specific therapies capable of swift adaptation to novel pathogens. As an illustration, a report released by the Minnesota Department of Health, a US-based state agency, indicated in April 2025 that in 2024, the percentage of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17%. Consequently, the growing impact of infectious diseases is fueling the expansion of the ribonucleic acid (RNA) therapy clinical trials market.
How Are Different Segment Groups Identified Within The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
Which Trends Are Shaping The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Landscape?
Leading companies in the ribonucleic acid (RNA) therapy clinical trials market are concentrating on developing innovative solutions, such as RNA-based antisense oligonucleotide therapy clinical trials, to target specific genetic sequences, modulate gene expression, and deliver highly precise treatments for genetic and rare diseases. An RNA-based antisense oligonucleotide therapy clinical trial refers to a study that investigates the use of short synthetic RNA strands to bind specific messenger RNA targets, aiming to modulate gene expression and treat genetic disorders. For instance, in December 2024, Sepul Bio, a France-based biotechnology company, initiated the LUNA Phase 2b clinical trial to evaluate ultevursen, an RNA-based antisense oligonucleotide therapy targeting mutations in exon 13 of the USH2A gene, which cause retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study will enroll 81 adults and children aged eight and above across multiple global sites. The therapy is intended for individuals with RP or non-syndromic RP due to exon 13 mutations in USH2A, which can be confirmed by genetic testing. The LUNA trial follows promising results from earlier Phase 1/2 studies, where ultevursen showed benefits in visual acuity, retinal sensitivity, and retinal structure.
Who Are The Prominent Players Across The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Access The Complete Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report:
Which Regional Market Leads The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Ribonucleic Acid Rna Sequencing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model